-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

Benzinga·09/25/2026 09:49:31
Listen to the news
BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.